Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2026

Conditions
B7H3CD276 AffibodyPET/CT Imaing
Interventions
DRUG

[68Ga] B7H3 Affibody-BCH

An affibody structure specifically targeting B7H3 was developed based on the B7H3 binding domain, and it was structurally optimized to yield a small molecular agent, B7H3 Affibody-BCH, suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3. By labeling with the radioactive isotope \^68Ga, this agent can be used for PET/CT diagnosis of solid tumors.

Trial Locations (1)

100142

RECRUITING

Xiangxi Meng, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER